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Abstract:
The overexpression of protein phosphatase 5 has been correlated to tumor cell reproduction
making it a candidate for small molecule drug therapy. Selective and potent inhibition of protein
phosphatase 2A (PP2A) enzyme has been previously achieved through the development of the
molecule fostriecin with key functionality being a lactone and unsaturated linear chain. The large
synthetic overhead of fostriecin has led to exploration of other small molecule inhibitors that
could mirror fostriecin’s interaction with the active site in the catalytic domain of PP5. The
naturally occurring inhibitor, cantharidin, is functionalized with an epoxy containing eleven
carbon chain to optimize binding with the active site of PP5 and to promote selectivity and
potency through unique interactions with the amino acid residues. The stereoisomers formed in
the Diels-Alder reaction between the robust dienophile N-phenylmaleimide and furfuryl alcohol
are isolated and identified. The biologically active exo confirmation is selectively recrystallized
and employed in further synthetic steps with the final product tested for inhibitory action against
the PP5 enzyme.
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Introduction:
Cancer is among the leading causes of death in America. The rapid reproduction of cells
is detrimental to the human body presenting a painful death for many individuals.1 Treatments
such as chemotherapy and radiation are familiar to most Americans; however, these techniques
are not completely effective in eliminating cancerous cells nor are they without dangerous side
effects such as lung damage and congestive heart failure.2 These therapies are also expensive and
time-consuming, yet still lack the specificity needed to prevent widespread side effects.
Research in cancer drug development has sought to understand what enables long term
cancer cells continued survival. For this reason, the division of biological enzymes known as
protein phosphatases have been taken into consideration due to their vital role in cell regulation.3
For instance, protein phosphatase 5 aids in the regulation of cell proliferation and apoptosis.
However, the overexpression of protein phosphatase 5, PP5, displayed a positive correlation to
tumor cell development in breast cancer, prostate cancer, and pancreatic cancer.4 It is
hypothesized that PP5 is aiding cancer cell proliferation by negatively regulating physiological
processes such as programmed cell death.5 Because of this possible link, protein phosphatase 5
has become an area of interest for anti-cancer drug research.
Various natural products have been shown to inhibit the activity of ser/thr protein
phosphatases. The derived natural product fostriecin (Figure 1) has successfully been used as an
antitumor agent in clinical trials.6 However, fostriecin requires more than 20 steps to synthesize
and is therefore not ideal for mass drug production.7 Current research aims to develop alternative
inhibitors that are similar in function to fostriecin. The naturally occurring inhibitor, cantharidin
(Figure 2), is a much smaller molecule than fostriecin that has been shown to successfully
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suppress the activity of the PP5.8 Unfortunately, dangerous side effects have resulted from
cantharidin’s lack of selectivity.8 Various derivatives of cantharidin have been able to increase
selectivity through new interactions between the inhibitor and active site.9 This study seeks to
use these previous results further increase selectivity. The effectiveness of the lactone
functionality of fostricien can be mimicked through a suitable equivalent such as an epoxy
functionality strategically tethered to a cantharidin scaffold.10 It is hypothesized that the epoxide
functionality will promote unique interactions with the polar amino acid residues, such as
Cysteine, found in and near the catalytic pocket which in turn increases potency while
maintaining specificity for PP5.
In this project, in addition to the introduction of new functionality, previous synthetic
pathways are refined by introducing a more robust starting material, N-phenylmaleimide , to the
Diels-Alder reaction. Diels-Alder adduct stereoisomers are isolated then identified through the
use of the two-dimensional NMR technique COSY.
O
O

HO3PO

O

OH
O

HO

Figure 1. Fostriecin

O
O

Figure 2. Cantharidin

Protein Phosphatases
Protein phosphorylation is a common cellular mechanism used to control intracellular
transduction pathways. This process is the attachment a phosphate group to an amino acid
residue such as serine or threonine by a protein kinase that can be subsequently
dephosphorylated by protein phosphatases.3 Reversible phosphorylation directly affects the
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interaction between proteins and thus regulates important cellular processes. Research has
focused largely on the two classes of enzymes that participate in these reactions: protein kinases
and protein phosphatases which contribute to cell growth and programmed cell death.
Deregulation of these enzymes, more specifically, abnormal protein serine/threonine phosphatase
activity, has been linked to several diseases including cancer.3-5

PP5 and Cancer Development
The protein phosphatase 5, PP5, has been found in many protein complexes that
contribute to signaling networks that regulate cellular proliferation and apoptosis. In a 2008
study, an analysis of human breast cancer cells revealed a correlation between the overexpression
of PP5 and cancer cell development.4 Researchers performed a follow-up study in order to
determine if overexpression of PP5 had a direct and positive effect on tumor growth. The
experiment compared tumor size development in mice that were injected with differing amounts
of PP5. It was concluded that PP5 overexpression was directly proportional to tumor size. There
exist several possible explanations to this relationship.
Prior studies have implied that the PP5 responds to cellular stress in altering its cell
growth regulatory mechanisms. Oxidative stress is known to be directly linked to gene mutation
and subsequently cancer cell proliferation. Substantial data has suggested that, during periods of
oxidative stress, PP5 protein levels increase.5 Such overexpression leads to an association with
apoptosis signal regulating kinase (ASK1). This correlation suggests the possible prevention of
apoptosis through inactivation of ASK1, therefore, allowing cells to survive in oxygen depleted
environments. PP5 is also reported to act as a negative regulator of the DNA damage repair
kinase, DNA-PKcs.5 Without repair, DNA damage is responsible for tumor cell development.

3

The relationships between PP5 and ASK1 and DNA-Pkcs demonstrate how the role of PP5 under
genomic stress can lead to negative effects including cancer progression. For these reasons PP5
has become an attractive target for anti-cancer drug development.
PP5: Target for Drug Development
An understanding of the enzyme’s structure and function is necessary for drug design
considerations. Protein phosphatases, PP1, PP2B, PP5, and PP2A, have very comparable
catalytic active sites.11 The amino acids of the catalytic core coordinate with two metal ions, Mn,
to provide the necessary interaction with the substrate and to allow dephosphorylation. The
substrate will also coordinate with the active site water molecule and metal ions. A competitive
inhibitor able to exploit these interactions would greatly limit enzyme activity.11
Protein phosphatase 5 is slightly unique in several attributes of its catalytic domain. First,
the tripartite tetratricopeptide-repeat (TPR) located at the N-terminus and the C-terminal interact
with one another blocking access to the catalytic site.12 Access to the catalytic domain is gained
after heat shock protein 90, HSP90, binds to the TPR. PP5 is activated only through the
chaperone HSP90; this step is essential to the function of PP5.13 PP5 is therefore involved in the
function of many HSP90 clients including the DNA-damage activated protein kinase and
apoptosis signaling kinase. Negative regulation of these kinases is directly fostered by the
sustained interaction between HSP90 and PP5; this relationship suggests the possible mechanism
behind sustained cancer cell proliferation and over expression of PP5.12-14 It has been
hypothesized that mutual inhibition may be necessary for optimal results.13 Therefore, these
biological relationships are considered when determining a small molecule inhibitor.

4

Fostriecin: Antitumor Antibiotic
The molecule fostriecin (Figure 1) is a potent and selective antitumor agent that provides
a novel mechanism for therapeutic implementation and has been tested in Phase I clinical trials at
the National Cancer Institute.6 Antitumor activity originates in the prevention of reversible the
phosphorylation of proteins that are necessary for the cell cycle.3 Dephosphorylation performed
by protein phosphatases is interrupted through the inhibitory action of fostriecin. However, the
effectiveness of fostriecin is in part due to its selective inhibition of PP2A (IC50=4.7 um) versus
PP1 (IC50 > 1000 μM).15 Contact with the catalytic grooves in PP2A, leads to covalent
interaction between the lactone of fostriecin and the nucleophilic amino acid residue Cys269.10
The absence of the Cys269 amino acid residue resulted in deselection of other protein
phosphatases.

Figure 3: Fostreicin within the active site of PP2A. Contacts within active site enable
selective inhibition.9

5

Fostriecin was originally isolated through the fermentation of beer. Throughout the
clinical trials, concerns were presented about the purity and storage stability of the naturally
isolated product.15 In order to confirm structural and stereochemical assignments, as well as
chemical purity, the synthetic assembly of fostriecin was necessary with total synthesis requiring
twenty steps.7 When looking towards future medicinal large-scale production, large numerousstep synthesis processes are not cost or time efficient. A smaller molecule requiring fewer
synthetic steps yet equal in effectiveness would be transformative for this field of study.
Research has turned to focus on naturally occurring small inhibitors for a potential model.

Overview of Cantharidin
Cantharidin is a naturally occurring inhibitor found in blister beetles. It has been used in
Chinese medicine for centuries for a wide range of ailments most commonly warts and
molluscum.8 Cantharidin consists of a six-membered ring where carbons 1 (C1) and 4 (C4) are
bridged by oxygen and carbon 2 (C2) and carbon 3 (C3) are fused with anhydride functionality
(Figure 2). Collectively, this core scaffold is 7-oxabicyclo[2.2.1]heptane. This novel tricyclic
system which consists of four oxygen atoms has been shown to be active as is the case in its
ability of this inhibitor to induce cell death and DNA breakage which explains its effectiveness
in dermatological removals. While activity is important, the potentially dangerous side effects of
cantharidin have led to its use being less attractive.8

6

Cantharidin and its Analogs
Cantharidin inhibits members of the serine/threonine-family protein phosphatases:
PP1CA, PP2CA, PP5C, and PP6C while PP4C was insensitive to cantharidin inhibition.9 The
catalytic pocket of these protein phosphatases displays strong correlation between the
carboxylate oxygens and the bridgehead oxygen of the inhibitor and the manganese ions.11
Specifically, studies on selectivity revealed close proximity between the oxygen bridgehead of
the inhibitor and both the manganese catalytic ions and the amino acid side chain (Phe446) of
PP5. Steric hindrance provided by the bulkier side chain (Trp257) in PP4C provided a plausible
explanation to minimal inhibitory action against PP4C as observed in the assay. Experiments
were further conducted to increase the selectivity for PP5 by testing various derivatives of the 7oxabicyclo [2.2.1] heptane scaffold.
The demethylated analog of cantharidin, norcantharidin (Figure 4), is easily synthesized
as well and has been shown to also be an effective inhibitor with potential anticancer
properties.16 The elimination of various negative side effects through the use of norcantharidin
over cantharidin has increased its use in drug testing.17 Further modifications to the structure
display potentially useful trends. Reduction of the C8-C9 double bond (Figure 5) when
substituted increased potency but did not increase selectivity for PP5. Addition of heteroatomic
functionality such as found in the propoxymethyl group at the C8 position (Figure 6) also
increased the inhibition against PP5 while largely deselecting for PP1C.9 The propoxymethyl
group allowed for favorable interaction through a supplementary hydrogen bond with a
neighboring amino acid residue while still avoiding steric clashes. These results are exploited in
further development of selective and potent inhibitors of PP5.
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Figure 4. Norcantharidin. Displaying demethylated analog of cantharidin with carbon
numbering.
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Figure 5. Reduction of C8/C9 bond. Displaying addition of substituent at C8 and reduction of
C8/C9 bond.
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Figure 6. Propoxymethyl substitution. Addition of substituent at position C8 promotes
selective inhibition.
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It is also observed that the inhibitory activity of norcantharidin correlates to whether or
not the starting structure is in anhydride or biscarboxylic acid form.11 Furthermore, research
results have suggested that the more active form of cantharidin and its derivatives is in fact the
acidic, ring-opened, form. In mirroring this form, the molecule endothall (Figure 8) is the
hydrolyzed derivative of cantharidin sharing the same 7-oxabicyclo[2.2.1]heptane-2,3dicarboxylic acid scaffold. Endothall exhibits competitive inhibition as both the carboxylic acid
oxygens and oxygen bridgehead coordinate with the metal ions to block water molecules from
participating in hydrolysis. However, the electrophilic carbon present in the anhydride is
vulnerable to a nucleophilic attack by a water molecule. Consequently, when working with the
carboxylic acid derivative, such as esters and amides, these moieties are liable to be removed
through hydrolysis reactions.15 Modifications at C8/C9 and C2/C3 positions diminish
susceptibility to hydrolysis and were found to be tolerated by PP5.9,15

O
OH
OH

O
O

Figure 8. Endothall. The Bis acid and active form of norcantharidin.
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Functionalization:
The catalytic mechanism of PPP-family ser/thr is very similar for all members.11 Subtle
differences in the catalytic pockets can be utilized to promote inhibitor specificity. Derivatives
containing additional functional groups are shown to increase potency and selectivity as
illustrated by propoxymethyl moiety at position C8.9 Increasing the carbon chain length from 3
to ten carbons also displayed an increase in selectivity as shown by the differing IC50 values of
PP5 and PP1.

Table 1: Comparison of differing IC50 values of cantharidin derivatives

Compound

R-group

PP5 IC50

PP1 IC50

R=H

1.0 μM

8.9 μM

R = CH2OCH2CH2CH3

0.7 μM

3.7 μM

R = CH2O(CH2)9CH3

14.3 μM

21.1 μM

11

Using fostriecin as a model system, next generation candidates can be prepared and tested
by employing specific functionality that potentially promotes covalent bonding to polar amino
acid residues. It is hypothesized that an epoxide could mirror the covalent interactions between
the lactone of fostriecin and the nucleophilic amino acid residue of the catalytic groove.9,10
Preliminary hypotheses support the endothall derivative containing tethered oxirane
functionalization would utilize close contact and interaction with the catalytic groove, leading to
an increase in potency and selectivity. Initial testing revealed enzyme inhibition of 4 nM and
therefore considerably more potent than previously tested molecules. Given the possibility of
hydrolysis of carboxylic acid derivatives, placements of the tethered epoxide at positions 1, 2,
and 5 of the norcantharidin scaffold will avoid hydrolysis while still demonstrating comparable
levels of inhibition. While the ideal length for the chain can be experimentally tested, the elevencarbon chain is an entry point exploiting contacts as shown in previously tested systems only to
be confirmed upon a proper study of tethered epoxy functionality. The results from the PP5
assays will guide future alterations to the chain length.
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Scheme 1. Synthetic Overview:
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Experimental methods:
1. General Considerations
2. Preparation of Undecenyl Tosylate
3. Preparation of 3-(Hydroxymethyl)furan
4. Diels-Alder Cycloaddition using N-Phenylmaleimide and Furan
5. Diels-Alder Cycloaddition using N-Phenylmaleimide and 2-(Hydroxymethyl)furan
6. Diels-Alder Cycloaddition using N-Phenylmaleimide and 3-(Hydroxymethyl)furan
7. Etherification of Hydroxymethyl Diels-Alder Adduct using Undecenyl Tosylate
8. Etherification of Hydroxymethyl Diels-Alder Adduct using Allyl Bromide
9. Hydrolysis and Ring Closure using N-Phenylmaleimide Diels-Alder Adduct
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1.

General Considerations

The NMR which generated all the spectra as part of this submission was a JEOL ECA-500
spectrometer. The software used to process all the corresponding data was JEOL DeltaTM
Version 5.0.4.4 (PC) or 5.2.1 (MAC). 1H NMR (500 MHz) spectra were obtained as solutions in
CDCl3. Chemical shifts were reported in parts per million (ppm) and referenced to δ 7.27 (1H
NMR). For the synthetic procedures performed, additional considerations consisted of the
following: TLC analyses were performed on flexible aluminum backed TLC plates with a
fluorescent indicator. Detection was conducted by UV absorption (254 nm) followed by
charring with 10% KMnO4 in water. Solutions were concentrated in vacuo using a rotary
evaporator. The resulting residue was purified using a silica gel column (70-230 mesh, 60 Å).
All chemicals used for synthetic procedures were reagent grade or better.

15

2. Preparation of Undecenyl Tosylate

OH

N

N
O
S
O

O

+
O
S
O

Cl

Et3N
CH2Cl2

10-Undecen-1-ol (3.62 mL, 18 mmol, 1.5 equiv) was added using a syringe to a round
bottomed flask (RBF) equipped with a magnetic stir bar, septum, and placed under a blanket of
argon. The setup was secured with clamp and placed on stir plate. Approximately 45 mL of
dichloromethane was added to the RBF while stirring. Next, 0.2 mL of 1-methylimidazole (0.2
mL, 2.52 mmol, 0.2 equiv.) and triethylamine (2.60 mL, 18 mmol, 1.5 equiv.) were added by
syringe. The reaction mixture was then externally cooled using an ice-bath. In a separate
container, tosyl chloride (2.3 g, 12 mmol, 1 equiv.) was dissolved using 20 mL of
dichloromethane. That suspension was then transferred to the reaction mixture using a disposable
glass Pasteur pipet. The reaction mixture was allowed to warm to room temperature and was
stirred for approximately 72 h. The organic layer was washed with deionized water and once
isolated, the organic layer was dried using anhydrous MgSO4 and concentrated in vacuum. The
crude tosylate was purified using column chromatography (SiO2; gradient system of
EtOAc/hexanes (hexanes, 1:16, 1:8, 1:4)) and yields averaged between 90-95%. Final product
was a viscous yellow oil. (SiO2, 1:16 EtOAc: hexanes, Rf = 0.3). δ 7.79 (d, 2H, CH, J = 8.6 Hz),
7.35 (d, 2H, CH, J = 7.5 Hz), 5.86-5.76 (m, 1H, CH), 5.01-4.92 (m, 2H, CH2), 4.02 (t, 2H, CH2, J
= 6.3 Hz), 2.45 (s, 3H, CH3), 2.03 (q, 2H, CH2, J = 8.0 Hz) 1.68-1.60 (m, 2H, CH2), 1.37-1.21
(m, 14H, CH2).
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3

Preparation of 3-Hydroxymethylfuran

O

O

+ NaBH4

HO

O

H

3-Furfural (1.94 g, 20 mmol, 1.75 mL) was added via syringe to a 250 mL RBF equipped with a
small magnetic stir bar. Approximately 100 mL of THF was next added to the RBF. The solution
was externally cooled using an ice bath while stirring under a blanket of argon. Sodium
borohydride (0.769 g, 20 mmol) was transferred to the reaction mixture portion wise. An
additional 1 mL of THF was used to completely transfer reductant to RBF. Reaction mixture
was kept externally cooled using an ice bath and allowed to stir under a blanket of argon for 48
h. The crude reaction mixture was diluted using tBuOMe (100 mL) and washed first with a
saturated aqueous solution of ammonium chloride (20 mL) followed by a saturated aqueous
solution of sodium chloride (20 mL). The organic layer was dried over anhydrous MgSO4 and
concentrated in vacuo while keeping the water bath at room temperature in order to minimize
loss of the volatile hydroxymethylfuran. The crude material was used as is once complete
conversion using TLC analysis was confirmed (SiO2, EtOAc:hexanes (1:1), Rf = 0.51).

17

4

Diels-Alder Cycloaddition using N-Phenylmaleimide and Furan

O

O
EtOAc

O

+

N

N

O
sealed tube

O

H2
10% Pd/C

O
O

O

N
O

N-phenylmaleimide (400 mg, 2.31 mmol, 1.0 equiv) was added to a sealed pressure flask
equipped with a stir bar and dissolved in 1.6 mL of hot ethyl acetate forming a 1.4 M solution.
Furan (252 µL, 3.5 mmol, 1.5 equiv) was next added via syringe once the reaction mixture was
allowed to cool back to room temperature. The pressure flask was sealed, placed in a sand bath
and externally heated to 100 °C. The reaction was allowed to stir for 16 h. The crude reaction
mixture was immediately hydrogenated 25 mg of 10% Pd/C. after transferring the material to a
Parr flask and diluted using as a ratio 20 mL of THF per gram of material. The hydrogenation
was set at 55 psi and allowed to mix for 1 h after purging the initial blanket of molecular
hydrogen three times. After removing the catalyst via filtration using a Celite pad, the product
was concentrated under reduced pressure and chromatographed (SiO2; EtOAc/hexanes (2:1)).
Reaction was replicated on several occasions with yields averaging between quantitative and
95%.1H NMR (CDCl3) δ 7.46 (t, 3H, CH, J = 7.5 Hz), 7.26 (d, 2H, CH, J = 5.7 Hz) 5.00-5.99
(m, 2H, CH), 3.05 (s, 2H, CH) 1.96-1.86 (m, 2H, CH2) 1.69-1.65 (m, 2H, CH2).
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5

Diels-Alder Cycloaddition using N-Phenylmaleimide and 2-Hydroxymethylfuran

O
O

O
EtOAc

+

N

N

O
sealed tube

HO

O

O

HO

O

H2

O

10% Pd/C
HO

N
O

2-Furfuryl alcohol (303 µL, 3 mmol, 1.5 equiv) and N-phenylmaleimide (400 mg, 2.3 mmol, 1.0
equiv) were added to a sealed pressure flask equipped with a magnetic stir bar and dissolved in
ethyl acetate (1.6 mL) to form a 1.4 M solution. The reaction was placed in a sand bath and
externally heated to 100 °C. Reaction was allowed to stir for 16 h. The crude reaction mixture
was immediately hydrogenated using 25 mg of 10% Pd/C after transferring the material to a Parr
flask and diluted using as a ratio 20 mL of THF per gram of material. The hydrogenation was set
at 55 psi and allowed to mix for 1 h after purging the initial blanket of molecular hydrogen three
times. After removing the catalyst via filtration using a Celite pad, the product was concentrated
under reduced pressure and chromatographed (SiO2; EtOAc/hexanes (2:1)). For purposes of
determining the isomeric composition, a small portion of chromatographed material was
recrystallized (EtOAc with hexanes) resulting in isomerically pure material. Reaction was
replicated on several occasions with yields of both the exo and endo adducts averaging between
quantitative and 95%. Recrystallized product was white powder. (SiO2, 6:1, Rf = 0.41) 1H NMR
(CDCl3) δ 7.50-7.46 (m, 2H, CH), 7.43-7.39 (m, 1H, CH), 7.28-7.25 (m, 2H + CDCl3, CH), 5.01
(d, 1H, CH, J = 5.2 Hz), 4.07 (dd, 2H, CH2,), 3.21-3.17 (m, 2H, CH2), 2.10-2.02 (m, 2H, CH2),
1.92-1.87 (m, 2H, CH2), 1.81-1.76 (m, 2H, CH2).
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Diels-Alder Cycloaddition using N-Phenylmaleimide and 3-Hydroxymethylfuran
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Using the identical protocol (setup, purification, and isolation) as described above using not 2(hydroxymethyl)furan but 3-(hydroxymethyl)furan (3 mmol, 1.5 equiv.), an average isolated
yield between quantitative and 95% yield was observed. Recrystallized product was white
powder. (SiO2, EtOAc:hexanes (5:1), Rf = 0.34) 1H NMR (CDCl3) δ 7.48 (t, 2H, CH, J = 6.3 Hz),
7.39 (t, 2H, CH, J = 9.2 Hz), 7.27-6.24 (m, 2H, CH+CDCl3), 4.97 (q, 2H, CH, J = 5.15 Hz), 3.7
(t ,CH, J =10.3 Hz), 3.48 (d, 1H, CH, J = 7.4 Hz), 3.02 (d, 1H, CH, J = 7.5 Hz), 2.58-2.51(m,
1H, CH), 2.09 (m, 1H, CH2), 1.32 (q, 1H, CH2, J = 6.8 Hz).
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Etherification of Hydroxymethyl Diels-Alder Adduct using Undecenyl tosylate
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The Diels-Alder adduct (680 mg, 2.5 mmol, 1 equiv) was dissolved in 6 mL of THF and placed
in a separate RBF. Sodium hydride (120 mg, 5.0 mmol, 2.0 equiv) was dissolved in 5 mL of
THF and externally cooled using an ice bath while under a blanket of argon. To this RBF was
transferred via syringe to the solution of Diels-Alder adduct. The reaction mixture was allowed
to gradually warm to room temperature and allowed to stir for 30 min at which time the reaction
mixture was externally cool again using an ice bath. The previously formed tosylate (973 mg, 3.0
mmol, 1.2 equiv) was dissolved in 2 mL of THF and added dropwise to reaction flask via
syringe. The reaction mixture was allowed to stir overnight. Upon quenching the reaction
mixture with aqueous HCl (0.1M), the reaction mixture was extracted with ethyl acetate, dried
with MgSO4, and filtered to remove the drying agent. Product was then concentrated under
vacuum and purified by column chromatography. (SiO2; gradient system of EtOAc/hexanes
(1:16, 1:8, 1:4, 6:1)). While successful in conducting the reaction, percent yield and spectrum are
not reported as the desired material was not isolated due to, what we suspect to be, multiple
competing side reactions.
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Etherification of Hydroxymethyl Diels-Alder Adduct using Allyl Bromide
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Using the identical protocol (setup, purification,and isolation) and replacing undecenyl tosylate
with allyl bromide (260 µL, 3 mmol, 1.2 equiv), a small amount of product as a yellow viscous oil
was isolated ~100 mg having the following spectral data: 1H NMR (CDCl3) δ 7.49 (t, 2H, CH, J
= 7.5 Hz), 7.42 (t, 2H, CH, J = 7.5 Hz), 7.26-7.23 (m, 1H, CH+CDCl3),5.99-5.91 (m, 1H, CH),
5.33 (dq, 1H, CH2, J = 7.6, 1.2 Hz) 5.23 (dd, 1H, CH2, J = 9.2, 1.2 Hz),4.97 (t, 1H, CH, J =5.2
Hz), 4.15(d, 2H, CH2, J = 5.7 Hz), 3.90 (dd, 2H, CH2, J = 11.5, 5.0 Hz), 3.73-3.67 (m, 2H, CH),
2.06-1.99 (m, 1H, CH2), 1.87-1.81 (m, 2H, CH2), 1.77-1.71 (m, 1H, CH2).
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Hydrolysis and Ring Closure using N-Phenylmaleimide Diels-Alder Adduct

O

O

1) KOH, heat
O

N
O

O

2) Ac2O

O
O

A 25 mL RBF was placed in a sand bath and externally warmed to 100 °C after the addition of
the following materials: 2.5 mL of DI water, 100 mg KOH (1.8 mmol), and 217 mg of the DielsAlder adduct ( 0.1 mmol). An additional 2.5 mL of water was added to RBF solution to assure
formation of a solution. A reflux condenser was attached to reaction set-up and the reaction
mixture was allowed to stir for 48 h. For this analysis, 2.5 mL of the reaction mixture was
transferred, concentrated in vacuo, and then dissolved in using 4 mL of DMF prior to the
addition of acetic anhydride (127 µL, 1.35 mmol, 3 equiv). Once added, the reaction mixture
was allowed to stir at room temperature for an additional 48 h. Analysis of the crude reaction
mixture upon multiple washes using EtOAc, drying over anhydrous MgSO4, and concentrating in
vacuo revealed the presence of the desired material confirming proof of principle. While
successful with conducting the reaction, percent yield and spectral data are not reported as the
desired product has not been properly isolated using optimized reaction conditions.
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Results and Discussion:
Forming the norcantharidin scaffold has been commonly achieved through reacting furan
and maleic anhydride. Addition of functional groups was consistently added to furfuryl alcohol
and the subsequent product reacted with maleic anhydride. However, subsequent reaction steps,
specifically Williamson ether synthesis and epoxidation of alkene, consistently resulted in low
yields due to competitive side reactions when specifically working with furan derivatives.
Average yields of over two dozen systems tested were between 20-40%. In seeking to minimize
the manipulation furan, altering the order of the synthetic pathway became necessary.
The likelihood of anhydride hydrolysis had previously not allowed for the Diels-Alder
reaction to be used as the first synthetic step. In contrast to the labile maleic anhydride knowing
that downstream synthetic steps may compromise the anhydride functionality, N-phenyl
maleimide was seen as a stable alternative. The strength of the imide bond alone sharply
decreased the possibility of a hydrolysis reaction from occurring. An addition, reaction
monitoring through thin-layer chromatography was also a challenge when using maleic
anhydride as the formed product was not UV active and, unfortunately, not readily charred using
as stain potassium permanganate. In contrast and by design de novo, N-phenylmaleimide
addressed both prior obstacles. Product formation and starting material consumption could now
be easily monitored throughout the reaction sequence. Therefore, N-phenylmaleimide is
considered a great candidate for Diels-Alder reactions in which the product can be further
manipulated in subsequent reactions. The imide can be transformed in a final synthetic step
restoring the anhydride that is has been shown key in inhibition of PP5.11
Diels-Alder reactions are known to produce asymmetric racemic mixtures favoring the
endo-adduct. However, co-crystal structures of PP5 and cantharidin reveal the exo confirmation
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allows for optimal interaction within the active site particularly with the manganese ions18. Prior
efforts were directed at developing a stereoselective synthesis protocol. Based on the knowledge
that exo-adduct is more thermodynamically favorable and that the cycloaddition is reversible,
reaction temperatures were increased to favor formation of the desired exo adduct. The
performed Diels-Alder reaction between furan, parent compound, and N-phenylmaleimide
resulted in the stereoselective product formation. With the reaction performed at elevated
temperatures, it was predicted that the thermodynamically favorable product, exo, would become
favored increasingly as the reaction proceeded.
The resulting NMR confirmed the formation of one isomer with only two peaks in the
diagnostic region due to the symmetry of the molecule.
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O
O

N
O

Spectrum 1. NMR spectrum of parent compound of Diels-Alder adduct following
hydrogenation. Note the limited peaks in the diagnostic region at δ5.0 (H7), and δ3.0 (H6,H2).

However, under replicated reaction conditions both isomers were present when replacing
furan with either 2-(hydroxymethyl)furan or 3-(hydroxymethyl)furan. .
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Spectrum 2. NMR spectrum of exo/endo mixture of Diels-Alder adduct following
hydrogenation. In comparison to parent compound, the diagnostic region contains significantly
more peaks between δ5.0-3.0.
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Enantioselective recrystallization of the exo product with a similar system, a methyl
substituent instead of hydroxymethyl at C1, was referred to when interpreting NMR spectrum.19
Chemical shifts of the literature values could not be used to confirm which stereoisomer was
generated. The isomers were separated using chromatographic techniques and further analyzed to
determine which chemical shifts correspond to each.
Initially, thin layer chromatography was used to determine a solvent system that allowed
for isomer separation. Separation was achieved using 5:1 EtOAc:hexanes. Translating this
information to normal phase chromatography, the separation of Diels-Alder products produced
stereochemically enriched samples of both the endo and exo isomers.
When interpreting the NMR spectra of the enriched samples, protons at positions 6 and 7
were the primary diagnostic peaks. Hydrogens at positions 6 and 2 are in the exo position when
overall product formed is endo (Figure 9). Conversely, the exo product results in hydrogens 6
and 2 being in the endo position (Figure 10).
The change in position of H6 and H2 produces changes in coupling with the
“neighboring” protons as it relates to position 7. The higher Rf valued product displayed a triplet
splitting pattern for the proton at position 7 (Spectrum 3, Table 2). This splitting pattern is in
contrast to the doublet displayed at the same position in the lower Rf isomer; that is, the proton at
position 7 is coupled to an additional hydrogen in the first isomer than the second (Spectrum 4,
Table 3).
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Figure 9. Endo Stereoisomer. Identified as higher Rf isomer through COSY NMR correlations.
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Figure 10. Exo Stereoisomer. Identified as lower Rf isomer through COSY NMR correlations.
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Spectrum 3: NMR spectrum displaying the diagnostic region of isomer of higher Rf
(enriched).Peaks of interest shown at δ 5.0 (H7), and δ 3.7-3.6 (H6).
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Spectrum 4: NMR spectrum displaying the diagnostic region of isomer of higher Rf (enriched).
Peaks of interest shown at δ 5.0 (H7), and δ 3.2-3.1 (H6).
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Table 2. Isomer of higher Rf (enriched):
Entry

Peak assignment

Splitting Pattern

Peak

Coupling

Image

(ppm)

Hz

of spectrum
reference

H7

H2, H6

1H, CH

t

4.97

2H, CH2

m

3.703.63
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5.7

Table 3. Isomer of lower Rf (enriched):
Entry

H7

H2, H6

Peak assignment

1H, CH

2H, CH2

Splitting Pattern

d

m

33

Peaks

Coupling

Image

(ppm)

Hz

of spectrum reference

4.99

5.15

3.19-3.16

However, the isomers could not be identified by the signal splitting patterns and as
detailed above, the model system used to confirm either stereoisomers, exclusive nor enriched,
did not align with the spectra generated using both 2-(hydroxymethyl)furan and 3(hydroxymethyl)furan as diene.19 Structural information provided by the NMR could however,
provide connectivity information given that the spin-spin coupling denoted by splitting patterns
alone was not able to reveal which protons were giving rise to the coupling displayed in
individual peaks. To garner more information on positioning of the diagnostic protons, twodimensional NMR became necessary. The popular 2D NMR technique, homonuclear correlation
spectroscopy or COSY, reveals homonuclear through bond correlations.20 If the nuclei of
protons have interaction and therefore display coupling, it is denoted by cross peak correlations.
The resulting COSY graph displays the one-dimensional NMR on both the x and y axis. Plot
points appear where a correlation exists; each peak will be correlated to itself resulting in a series
of linear points whereas nonlinear points display correlations between protons of differing
chemical shifts. These nonlinear points reveal which protons are connected to one another
through bond. Therefore, combining the data of one-dimensional and two-dimensional NMR
gives both structural information and connectivity information. Relative stereochemical
positioning of the protons is directly revealed through the correlations or perhaps more
importantly, lack of correlations displayed by the two-dimensional NMR.
Furthermore, literature sources highlighted the effects of bond angle on the coupling
constant J between the protons Ha-C-C-Hb.21 The Newman projection displays that as the
dihedral angle between Ha and Hb approaches 90° the coupling constant approaches 0 Hz.
Conversely, as the bond angle approaches 0° or 180°, the larger the coupling constant becomes.
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In the model system, bicyclo[2.2.1]heptan-2-one, this correlation between the dihedral bond
angle and coupling values is clearly reflected.

Figure 11. Bicyclo[2.2.1]heptan-2-one. Used as model system in establishing relationship
between dihedral bond angle and coupling.
H6n-C-C-H1, where the dihedral bond angle is 44.91° coupling is 4.7 Hz. H6x-C-C-H1, where the
bond angle is 77.26°, coupling is 0.1 Hz.20 Dihedral bond angles were derived using Spartan
software. Given the similarity between the two systems highlighting the proton at the bridgehead
carbon and the adjacent methylene, the synthesized Diels-Alder stereoisomers using the
decorated furan derivatives are predicted to follow this pattern. In the synthesized endo-adduct,
the dihedral bond angle, as determined by Spartan, of H7-C-C-H6x is 36.23° while the dihedral
bond angle of H7-C-C-H6n of the exo-adduct is 81.91°. Therefore, based on the literature values,
positioned hydrogen (H6x) of the endo-Diels-Alder adduct will display far greater coupling to the
(H7) than the (H6n) of the exo-adduct.21 This coupling will be reflected in the given correlations
of the COSY NMR.
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Figure 12. Diagnostic correlations of Endo Diels-Alder adduct. Dihedral bond angle of H7-C-CH6x is 36.23°. Coupling is expected to be significant.
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Figure 13. Diagnostic correlations of Exo Diels-Alder adduct. Dihedral bond angle of H7-C-CH6n is 81.91°. Coupling is expected to be greatly reduced.
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The higher Rf isomer displayed nonlinear spots between the H7 and H6 peaks as illustrated in the
COSY spectrum below.

H7

H6

H6

H7

Spectrum 5. COSY correlations of higher Rf product. Note the highlighted areas which confirm
correlations between protons of positions 6 and 7.
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In contrast, the isomer of lower Rf value, did not show non-linear correlation between the
respective peaks.

H7

H6

H6

H7

Spectrum 6. COSY correlations of lower Rf product. Note the highlighted areas which confirm
the absence of correlations between protons of positions 6 and 7.
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From these correlations it was deduced that the triplet displayed by the first isomer included
coupling with H6 and therefore H6 is in the exo position (Figure 12, Spectrum 5). Furthermore, it
is also deduced that the doublet displayed by the H7 of the second stereoisomer did not include
coupling with H6 leading to the conclusion that H6 is representative of the endo isomer (Figure
13, Spectrum 6). Combining this data leads to the conclusion that the first isomer is the endo
Diels-Alder adduct and the second isomer is the exo Diels-Alder adduct.
Addition of functional groups to furan made isolation of a singular isomer through
stereoselective synthesis unviable. Column chromatography and identification of the isomers
was necessary to confirm the isolation of the desired exo isomer through recrystallization
techniques. Only by having both isomers either separated or enriched and conducting this type of
analysis is it possible to offer stereochemical confirmation. The results given by COSY spectral
analysis confirmed the literature predictions of effect of dihedral bond angle on coupling.
Isolation of the exo stereoisomer allowed for advancement of this system to be pursued.
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Conclusion:
Initial synthetic attempts consistently resulted in low yields as a result of competitive side
reactions. After the testing of various pathways, it was revealed that the reactivity of furan made
it unsuitable for continuous manipulation. Furan derivatization was limited by performing the
Diels-Alder reaction as the first synthetic step. Replacing the reactive maleic anhydride with Nphenylmaleimide drastically improved the stability resulting in higher yields and enabling
breadth when considering the addition of functionality. Original reaction preps sought to isolate
the exo stereoisomer exclusively. However, the addition of the hydroxymethyl substituent
resulted in a mixture of both stereoisomers. Preliminary NMR results were unable to definitely
identify the isomers. The two-dimensional NMR technique COSY gave diagnostic correlations
between the protons bound to positions 6 and 7 that when compared to the known effect of
dihedral angle on coupling gave the affirmative stereoisomer determination. The exo isomer,
with key peaks at 4.99 ppm and 3.19-3.16 ppm, was isolated through chromatography followed
by recrystallization. This final product will be carried on in further synthetic steps by other
members of the research lab. Work will focus on modifying synthesis protocol for both
etherification using undecenyl-tosylate and anhydride formation. Epoxidation will be the final
step before biological testing. Modification to the reaction protocol seek to develop a unified,
high-yielding synthetic approach toward the assembly of decorated norcantharidin scaffolds that
can be easily subjected to biological testing.
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APPENDIX B: IMAGES FOR REACTION SETUP
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Image 1: Use of round-bottom bottle with wire bail closure for the cycloaddition of 2hydroxymethylfuran and N-phenylmaleimide. Note: Hot plate setting was 100 °C.
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Image 2. Parr shaker (medium pressure hydrogenation apparatus)

53

